SCR 6852
Alternative Names: SCR-6852; SIM-0270Latest Information Update: 25 Aug 2025
At a glance
- Originator Jiangsu Simcere Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer
- Preclinical Brain metastases
Most Recent Events
- 22 Aug 2025 SCR 6852 is still in phase-I development in Breast-cancer(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (PO, Capsule) (NCT05293964)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (PO, Capsule)
- 30 May 2025 Efficacy and adverse events data from a phase I trial in Breast cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)